An 8-week, Multicenter, Randomized, Double-blind, Placebo and Active-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of 3 Doses of CHF 718 pMDI (HFA Beclomethasone Dipropionate Via Pressured Metered Dose Inhaler) in Asthmatic Subjects
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2018
At a glance
- Drugs Beclometasone
- Indications Asthma
- Focus Therapeutic Use
- Acronyms BEAM
- Sponsors Chiesi Farmaceutici SpA
- 15 Oct 2018 Planned End Date changed from 21 Sep 2018 to 23 Nov 2018.
- 15 Oct 2018 Planned primary completion date changed from 21 Sep 2018 to 30 Nov 2018.
- 31 Aug 2018 Biomarkers information updated